Precision Biosciences Inc. (DTIL) is a leading life sciences company that specializes in genome editing technology. Established in 2006 and based in Durham, North Carolina, the company utilizes a proprietary platform named the ARCUS® platform, designed for effective genomic modifications in a range of organisms and cell types.
The heart of the company lies in its commitment to developing life-altering therapies for patients with genetic disorders or cancers that could be significantly addressed by gene editing. By using the ARCUS® Genome Editing technique, Precision Biosciences aims to overcome challenges associated with traditional genome editing techniques.
The company has formed several partnerships with pharmaceutical companies and biomedical researchers to apply their technology in various therapeutic areas. Its genome editing technique has potential applications in diverse fields, including human therapy, agricultural biotechnology, and industrial biotechnology.
In the field of human therapy, Precision Biosciences' most advanced program is in the immune-oncology space with their proprietary allogeneic CAR T therapy, targeting various hematological malignancies and solid tumors. The unique aspect of their therapy is the "off-the-shelf" availability, unlike most available CAR T therapies which require individualized processing for each patient.
In the ag-bio section, Precision Biosciences' team has developed a new, high-quality form of healthy wheat by removing the gene responsible for a troublesome allergen, which benefits millions of people globally who are sensitive to it.
Similarly, in the spectrum of industrial bio, Precision Biosciences works to perfect the yeast strains that produce vinegar for both medicinal and industrial applications.
Furthermore, Precision's team of committed individuals has a unique blend of skillsets in molecular biology, chemistry, and engineering that fuel their innovations. The company has consistently shown the ability to deliver competitive solutions in the area of genomic correction and transformation.
Precisely focused on its mission to “transform life,” Precision Biosciences continues to make strides to bring about therapeutic advances that will enhance the lives of patients with genetic diseases and cancer. The team at Precision Biosciences believes in the immense potential of genome editing and is consciously working towards realizing significant advancements in the field. With strong leadership, an innovative spirit, and steadfast determination, Precision Biosciences is well poised to continue leading the frontiers of genomic medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides an AI-generated analysis of Precision Biosciences Inc. (NASDAQ: DTIL), highlighting a weak near- and mid-term sentiment but a positive long-term outlook. It details three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, and includes a multi-timeframe signal analysis indicating strong long-term potential despite current weakness. The report emphasizes an exceptional 76.5:1 risk-reward setup.
This article analyzes Precision Biosciences Inc. (NASDAQ: DTIL) using AI models to suggest trading strategies based on different risk profiles. It highlights weak near-term sentiment but strong long-term potential, providing specific entry, target, and stop-loss zones for position, momentum, and risk-hedging strategies. The analysis includes multi-timeframe signals, support, and resistance levels.
This article provides a price-driven insight into Precision Biosciences Inc. (NASDAQ: DTIL) for a rule-based strategy, highlighting weak near-term sentiment but strong mid and long-term outlooks. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes a favorable 93.0:1 risk-reward setup targeting a 24.5% gain versus 0.3% risk.
Precision BioSciences Inc (NASDAQ: DTIL) has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, a significant milestone for its gene editing therapy for Duchenne muscular dystrophy. Despite this clinical progress, the company appears substantially overvalued, with its stock trading 373.3% above its GF Value™ and a Price-to-Sales ratio slightly exceeding its historical median, reflecting expectations of future revenue growth while the company remains unprofitable. Insider and guru activity shows net selling and trimmed positions, suggesting cautious sentiment among informed investors.
Precision BioSciences has initiated its Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. The trial has dosed its first patient and is recruiting ambulatory DMD patients aged 2-7 with specific genetic mutations. Initial safety data from the study is anticipated by the end of 2026.
Precision BioSciences Inc (DTIL) is considered 355.6% overvalued according to GuruFocus's GF Value™ despite recent positive stock momentum. The company, focused on gene editing technology, faces significant financial challenges including unprofitability and negative cash flow, reflected in its low GF Score™ of 47 out of 100, and net insider selling. Investors are cautioned to weigh these factors against the market's optimistic expectations and upcoming clinical data presentations.
Precision BioSciences, Inc. (NASDAQ:DTIL) recently released a disappointing second-quarter report with revenues significantly lower than predicted and increased per-share losses. Analysts have subsequently cut next year's revenue estimates and raised loss per share forecasts, indicating a change in sentiment. Despite this, the consensus price target remains unchanged, though there's a wide range in individual analyst valuations.
Wall Street Zen has downgraded Precision BioSciences (NASDAQ:DTIL) to a "Sell" rating from "Hold," despite a broader analyst consensus of "Moderate Buy" with a $32.25 price target. The company recently reported a quarterly loss of $1.26 per share, missing analyst expectations. Institutional investors hold approximately 37.99% of the stock, with several hedge funds increasing their positions in the clinical-stage genome-editing company.